Literature DB >> 26684821

HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls.

Katherine W Kooij1, Ferdinand W N M Wit, Judith Schouten, Marc van der Valk, Mieke H Godfried, Ineke G Stolte, Maria Prins, Julian Falutz, Peter Reiss.   

Abstract

BACKGROUND: Frailty is an age-related syndrome of decreased physiological reserve and resistance to stressors, associated with increased morbidity and mortality in the general elderly population. An increased prevalence of frailty has been reported amongst HIV-infected individuals.
METHODS: Fried frailty phenotype was systematically assessed in predominantly virologically suppressed HIV type 1 (HIV-1)-infected and otherwise comparable HIV-uninfected participants aged at least 45 at enrollment into the AGEhIV Cohort Study. Multivariable ordinal logistic regression was used to investigate associations between HIV- and antiretroviral therapy-related covariates, markers of inflammation and body composition and prefrailty/frailty.
RESULTS: Data were available for 521 HIV-infected and 513 HIV-uninfected individuals. Prevalence of frailty (10.6 versus 2.7%) and prefrailty (50.7 versus 36.3%) were significantly higher in HIV-infected individuals (Ptrend < 0.001). HIV infection remained statistically significantly associated with prefrailty/frailty after adjustment for age, sex, race/ethnicity, smoking, hepatitis C infection, comorbidities and depression [adjusted odds ratio (ORadj) 2.16, P < 0.001]. A higher waist-to-hip ratio attenuated the coefficient of HIV-infected status (ORadj 1.93, P < 0.001), but not waist- or hip-circumference individually or markers of inflammation. Within the HIV-infected group, parameters related to body composition were most strongly and independently associated with prefrailty/frailty: current BMI less than 20 kg/m2 (OR 2.83, P = 0.01), nadir BMI less than 20 kg/m2 (OR 2.51, P = 0.001) and waist-to-hip ratio (OR 1.79 per 0.1 higher, P < 0.001).
CONCLUSION: HIV infection was independently associated with prefrailty/frailty in middle-aged HIV-infected patients compared with HIV-uninfected controls. This partly may be mediated by the higher waist- and lower hip-circumference in the HIV-infected individuals, potentially partially caused by lipodystrophy, and in part be a consequence of historic weight loss associated with advanced HIV-disease.

Entities:  

Mesh:

Year:  2016        PMID: 26684821     DOI: 10.1097/QAD.0000000000000910

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  44 in total

1.  Abdominal obesity, sarcopenia, and osteoporosis are associated with frailty in men living with and without HIV.

Authors:  Kellie L Hawkins; Long Zhang; Derek K Ng; Keri N Althoff; Frank J Palella; Lawrence A Kingsley; Lisa P Jacobson; Joseph B Margolick; Jordan E Lake; Todd T Brown; Kristine M Erlandson
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

Review 2.  Geriatric syndromes: new frontiers in HIV and sarcopenia.

Authors:  Kellie L Hawkins; Todd T Brown; Joseph B Margolick; Kristine M Erlandson
Journal:  AIDS       Date:  2017-06-01       Impact factor: 4.177

3.  Physical Function and Frailty in HIV.

Authors:  Kristine M Erlandson
Journal:  Top Antivir Med       Date:  2020 Dec-Jan

4.  Psychosocial Correlates of Frailty Among HIV-Infected and HIV-Uninfected Adults.

Authors:  Anna A Rubtsova; María J Marquine; Colin Depp; Marcia Holstad; Ronald J Ellis; Scott Letendre; Dilip V Jeste; David J Moore
Journal:  Behav Med       Date:  2018-11-15       Impact factor: 3.104

Review 5.  Probing the Interface of HIV and Inflammaging.

Authors:  Scott F Sieg; Carey L Shive; Soumya Panigrahi; Michael L Freeman
Journal:  Curr HIV/AIDS Rep       Date:  2021-03-11       Impact factor: 5.071

6.  The Current State of HIV and Aging: Findings Presented at the 10th International Workshop on HIV and Aging.

Authors:  Stephanie Shiau; Alexis A Bender; Jane A O'Halloran; Erin Sundermann; Juhi Aggarwal; Keri N Althoff; Jason V Baker; Steven Deeks; Linda P Fried; Stephen Karpiak; Maile Y Karris; Thomas D Marcotte; Jean B Nachega; Joseph B Margolick; Kristine M Erlandson; David J Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2020-09-23       Impact factor: 2.205

7.  Inflammation, Immune Activation, Immunosenescence, and Hormonal Biomarkers in the Frailty-Related Phenotype of Men With or at Risk for HIV Infection.

Authors:  Kristine M Erlandson; Derek K Ng; Lisa P Jacobson; Joseph B Margolick; Adrian S Dobs; Frank J Palella; Jordan E Lake; Hanhvy Bui; Lawrence Kingsley; Todd T Brown
Journal:  J Infect Dis       Date:  2017-01-15       Impact factor: 5.226

8.  Lean mass declines consistently over 10 years in people living with HIV on antiretroviral therapy, with patterns differing by sex.

Authors:  Paula Debroy; Jordan E Lake; Myung Sim; Kristine M Erlandson; Julian Falutz; Carla M Prado; Todd T Brown; Giovanni Guaraldi; The Modena Hiv Metabolic Cohort Team
Journal:  Antivir Ther       Date:  2019

Review 9.  Inflammation, Immune Activation, and Antiretroviral Therapy in HIV.

Authors:  Corrilynn O Hileman; Nicholas T Funderburg
Journal:  Curr HIV/AIDS Rep       Date:  2017-06       Impact factor: 5.071

10.  Long-term body composition changes in antiretroviral-treated HIV-infected individuals.

Authors:  Philip M Grant; Douglas Kitch; Grace A McComsey; Ann C Collier; Benedetta Bartali; Susan L Koletar; Kristine M Erlandson; Jordan E Lake; Michael T Yin; Kathy Melbourne; Belinda Ha; Todd T Brown
Journal:  AIDS       Date:  2016-11-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.